Literature DB >> 6682696

Mutagenic activity and identification of excreted platinum in human and rat urine and rat plasma after administration of cisplatin.

R Safirstein, M Daye, J B Guttenplan.   

Abstract

Cisplatin and its biotransformation products were analyzed in human and rat urine and in plasma from rats. Analyses were performed using high performance liquid chromatography (HPLC). Microbial mutagenesis assays were performed on effluents from the chromatographic system. After intravenous administration to man (50 mg/m2) and intravenous and intraperitoneal administration to rats (5-10 mg/kg), platinum was excreted in the urine in a form that co-eluted mainly with cisplatin. Unbound drug in the plasma co-eluted with cisplatin. Furthermore excreted platinum exhibited mutagenic and chemical reactivity similar to that of cisplatin. We conclude that the principal form of free platinum circulating in blood and excreted in urine is cisplatin.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6682696     DOI: 10.1016/0304-3835(83)90244-6

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  6 in total

Review 1.  The risks of handling cytotoxic drugs. II. Recommendations for working with cytotoxic drugs.

Authors:  G P Kaijser; W J Underberg; J H Beijnen
Journal:  Pharm Weekbl Sci       Date:  1990-12-14

Review 2.  The risks of handling cytotoxic drugs. I. Methods of testing exposure.

Authors:  G P Kaijser; W J Underberg; J H Beijnen
Journal:  Pharm Weekbl Sci       Date:  1990-12-14

3.  A model for ultrafilterable plasma platinum disposition in patients treated with cisplatin.

Authors:  P A Reece; I Stafford; J Russell; M Khan; P G Gill
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 4.  Platinum antitumour agents: a review of (bio)analysis.

Authors:  T J Hodes; W J Underberg; G Los; J H Beijnen
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

5.  Nonlinear renal clearance of ultrafilterable platinum in patients treated with cis-dichlorodiammineplatinum (II).

Authors:  P A Reece; I Stafford; J Russell; P G Gill
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

6.  Liquid Chromatography Electrospray Ionization Tandem Mass Spectrometric (LC/ESI-MS/MS) Study for the Identification and Characterization of In Vivo Metabolites of Cisplatin in Rat Kidney Cancer Tissues: Online Hydrogen/Deuterium (H/D) Exchange Study.

Authors:  Raju Bandu; Hyun Soo Ahn; Joon Won Lee; Yong Woo Kim; Seon Hee Choi; Hak Jin Kim; Kwang Pyo Kim
Journal:  PLoS One       Date:  2015-08-05       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.